Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine | Eli Lilly and Company

Eli Lilly and Company·May 16

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Results from a study on orforglipron, an oral GLP-1, have been published, showing it to be associated with meaningful weight loss and cardiometabolic improvements. The treatment has been approved for obesity, with some reports indicating it can be taken without food or water restrictions. The extent of its approval and specific uses, such as for type 2 diabetes or menopause-related weight loss, are not entirely clear.

Full coverage

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

PR Newswire·Jun 7

Oral GLP-1 Orforglipron Is Approved for Obesity

Pharmacy Times·May 20

Eli Lilly's oral GLP-1 pill may help people with Type 2 diabetes lose 'significant' weight, study finds

ABC News - Breaking News, Latest News and Videos·Feb 11

Eli Lilly’s Investigational Oral GLP-1 Receptor Agonist Demonstrates Significant Weight Loss

Applied Clinical Trials Online·Aug 7

Orforglipron Demonstrates Superior Blood Sugar Control Compared With Oral Semaglutide

Drug Topics·Feb 26

FuturHealth Among the First to Offer Eli Lilly's Oral GLP-1, Orforglipron, Expanding Access to Next-Generation, Non-Injectable Treatment

Morningstar·Apr 28

Investigational Oral GLP-1 RA, Orforglipron, Yields Dose-Dependent Weight Loss in Phase 3 Trial

Patient Care Online·Sep 17

FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions

Manufacturing Chemist·Apr 3

View original report at Eli Lilly and Company ↗

Fetching the latest headlines…